Aeris Biotechnologies
A Groundbreaking Approach to Asthma & Allergy
Overview
Raised: $95,200
Rolling Commitments ($USD)
06/29/2023
$300
8
2021
Healthcare & Pharmaceuticals
Biotech
B2C
Medium
High
Balance Sheet
Cash and Cash Equivalents |
$33,242 |
Total Assets |
$33,242 |
Accounts Payable & Accrued Liabilities |
$104,548 |
Long Term Debt |
$50,000 |
Total Liabilities |
$104,548 |
Total Stockholders' Equity |
$-71,306 |
Total Liabilities and Equity |
$33,242 |
Statement of Comprehensive Income Information
Net Income |
$0 |
Earnings Per Share - Basic |
$0.00 |
Earnings Per Share - Diluted |
$0.00 |
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual